Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Rating of "Buy" from Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given an average recommendation of "Buy" by the seven analysts that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.17.

Several analysts have commented on CNTX shares. D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th.

Context Therapeutics Stock Down 6.9 %

CNTX traded down $0.05 during trading on Monday, hitting $0.74. 101,050 shares of the company's stock were exchanged, compared to its average volume of 387,524. The stock has a market cap of $66.07 million, a P/E ratio of -0.81 and a beta of 2.06. The business's 50 day moving average is $0.84 and its two-hundred day moving average is $1.40. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75.

Remove Ads

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. On average, sell-side analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently added to or reduced their stakes in the business. State Street Corp increased its position in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Clear Harbor Asset Management LLC lifted its holdings in shares of Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after acquiring an additional 21,804 shares during the last quarter. Jane Street Group LLC bought a new position in Context Therapeutics in the fourth quarter valued at $29,000. Citadel Advisors LLC purchased a new stake in Context Therapeutics during the fourth quarter valued at about $31,000. Finally, Millennium Management LLC increased its position in shares of Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after purchasing an additional 34,835 shares during the last quarter. Institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.